FDA approves Boehringer's anti-clotting drug Pradaxa

10/19/2010 | Bloomberg

The FDA has approved 75- and 150-milligram capsules of Boehringer Ingelheim's blood thinner Pradaxa to prevent stroke in patients with atrial fibrillation. "Unlike warfarin, which requires patients to undergo periodic monitoring with blood tests, such monitoring is not necessary for Pradaxa," an FDA official said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC